Aa­van­tiBio lands man­u­fac­tur­ing part­ner in Friedre­ich's Atax­ia pro­gram; NC Re­search Tri­an­gle lands an­oth­er CD­MO

Aa­van­tiBio and Re­silience have an­nounced a col­lab­o­ra­tion to man­u­fac­ture a pipeline of ther­a­pies, in­clud­ing Aa­van­tiBio’s Friedre­ich’s Atax­ia pro­gram, the com­pa­ny an­nounced Thurs­day.

The ade­no-as­so­ci­at­ed vi­ral vec­tor-based can­di­date is cur­rent­ly in Phase I/II tri­als in the US and Eu­rope, and Re­silience will pro­vide cell lines and vi­ral banks for the drug’s first in-hu­man tri­als. The drug will be man­u­fac­tured at Re­silience’s 183,000-square-foot fa­cil­i­ty in Alachua, FL.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER